ROCHE_WEB THUMBNAIL
April 16, 2024

Faricimab – The Fight Against Retinal Diseases

Faricimab (Vabysmo) is the first approved bispecific antibody uniquely engineered to block two key pathways driving retinal vascular disease by…

popular posts
Apr11_Article
April 11, 2025

NexThera, Oculis and Bayer Report Advances in Retinal Disease Therapies

latest posts
FDA Rejects Regeneron’s Bid to Extend EYLEA HD Dosing Beyond 16 Weeks
April 22, 2025

FDA Rejects Regeneron’s sBLA to Extend EYLEA HD Dosing Interval

Apr11_Article
April 11, 2025

NexThera, Oculis and Bayer Report Advances in Retinal Disease Therapies

Article 2
April 4, 2025

Advances in AMD and DME Take Center Stage at APAO 2025

Thumbnail article _ 1200x675_bayer Eylea 8m
February 12, 2025

Bayer’s Aflibercept 8 mg Eyes Six-Month Stretch Between Treatments

Website thumbnail FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes Related Blindness (1)
February 5, 2025

FDA Approves the First Anti-VEGF Port Delivery System for Diabetic Macular Edema

ROCHE_WEB THUMBNAIL
April 16, 2024

Faricimab – The Fight Against Retinal Diseases

Discover our fascinating content at issuu

explore